Business description
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Management board & Supervisory board
| CEO |
| Jean-Christophe Tellier |
| Management board |
| Sandrine Dufour, Charl van Zyl, Dhaval Patel, Emmanuel Caeymaex, Iris Löw-Friedrich, Jean Luc Fleurial, Kirsten Lund-Jurgensen, Denelle Waynick Johnson |
| Supervisory board |
| Jonathan Peacock, Fiona du Monceau, Jean-Christophe Tellier, Jan Berger, Maëlys Castella, Kay Davies, Albrecht De Graeve, Susan Gasser, Pierre Gurdjian, Charles-Antoine Janssen, Cyril Janssen, Cédric van Rijckevorsel, Ulf Wiinberg, Viviane Monges |
Company data
| Name: |
UCB SA |
| Address: |
Allée de la Recherche 60,B-1070 Brussels |
| Phone: |
+32-2-559-9999 |
| Fax: |
+32-2-559-9900 |
| E-mail: |
contactucb@ucb.com
|
| Internet: |
www.ucb.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12/31 |
| Free Float: |
44.83% |
| IPO date: |
- |
